Novo Nordisk seeks U.S., European approval of diabetes drug

05/27/2008 | Bloomberg

Danish firm Novo Nordisk is seeking marketing approval for diabetes treatment liraglitude in the U.S. and Europe in a bid to launch the drug next year. Liraglitude is expected to compete with similar drugs being developed by Sanofi-Aventis and Novartis. The drug is based on glucagon-like peptide-1, a hormone that activates insulin production in the pancreas.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI